Economic benefit of fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) by baseline blood eosinophil (EOS) count in COPD in the UK - The IMPACT trial - Milan 2023

Navigating the latest chronic obstructive pulmonary disease therapeutic trends

Chair(s): Gareth Hynes, Carolina Gotera

Session type: Poster session

Economic benefit of fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) by baseline blood eosinophil (EOS) count in COPD in the UK - The IMPACT trial

Stephen G Noorduyn

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Extra-fine Particle Inhaled Corticosteroids Influence on the Risk of Hospitalization due to Pneumonia in Patients with Chronic Obstructive Pulmonary Disease - A Populations-Based Cohort Study

Christian Kjer Heerfordt

Abstract

Tulobuterol Transdermal Patch as an add on therapy in Stable COPD

Beena Thomas

Poster

Abstract

Economic benefit of fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) by baseline blood eosinophil (EOS) count in COPD in the UK - The IMPACT trial

Stephen G Noorduyn

Poster

Abstract

The national development in the use of inhaled corticosteroid treatment for chronic obstructive pulmonary disease in Denmark from 1995 to 2018

Allan Klitgaard

Poster

Abstract

Safety and efficacy of home initiation of chronic non-invasive ventilation in patients with severe COPD and chronic hypercapnic respiratory failure.

Emma Parkes

Poster

Abstract

A meta-analysis on the importance of peak inspiratory flow variance in simplifying DPI prescribing for COPD patients

Monbi Stefanova Chakma

Poster

Abstract

Persistence to inhaled long-acting maintenance therapy in patients with COPD in UK routine clinical practice

Kieran J. Rothnie

Poster

Abstract

Experience of clinicians on dual bronchodilator therapy in COPD (EXPAND) in Nepal

Ramesh Chokhani

Poster

Abstract

Step up to ICS/LAMA/LABA vs switch to LAMA/LABA in patients with COPD on ICS/LABA: post hoc analysis of KRONOS

Dave Singh

Poster

Abstract

Does azithromycin modulate cardiovascular risk following acute pulmonary exacerbations of chronic obstructive pulmonary disease?

Freddy Frost

Poster

Abstract

Clinically important deterioration and COPD treatments: a pairwise meta-analysis

Gian Marco Manzetti

Poster

Abstract

Adherence to COPD treatment and concomitant diseases: is there influence ?

Nataliia Slepchenko

Poster

Abstract

Adherence to COPD treatment during the war: can we maintain the previously achieved results ?

Nataliia Slepchenko

Poster

Abstract

Inhaler technique mastery in elderly COPD patients with cognitive impairment trained on different inhaler devices

Federico Lavorini

Poster

Abstract

The Impact of Extrafine Beclometasone/Formoterol/Glycopyrronium on Sleep disturbance in Chronic Obstructive Pulmonary Disease (COPD) in an Italian Context of Real Life: The TRITRIAL Study.

Alessio Piraino

Poster

Abstract

Characteristics of COPD patients initiating budesonide/glycopyrronium/formoterol (BGF) and other triple therapy in Japan: a health-care claims-based real-world database study (MITOS program)

Koichiro Takahashi

Poster

Abstract

Heterogeneous treatment effect estimation of LABA/LAMA/ICS on COPD exacerbation risk in the IMPACT trial

Kenneth Verstraete

Abstract

Methods to assess adherence to COPD medication in electronic healthcare databases: a systematic review

Delphine Vauterin

Poster

Abstract

Inhaled triple therapy versus dual bronchodilation in smokers patients with COPD: a 3-year observational study

Angelo Petroianni

Poster

Abstract

CDN Connection Issue

The ERS International Congress 2023, Milan

#{title}